New hope for hard-to-treat nose and throat cancer?
Disease control
Recruiting now
This study tests whether a new combination of two drugs (MRG003 and pucotenlimab) works better than standard chemotherapy for people whose nasopharyngeal cancer has come back or spread. About 446 adults who have already tried at least one other treatment will take part. The goal …
Phase: PHASE3 • Sponsor: Shanghai Miracogen Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC